BRCA-话题@MedSci

#BRCA#

135篇内容 | 3616人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594061, encodeId=3890159406171, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗, objectType=article, longId=195327, objectId=2cf719532e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cf719532e2a, replyNumber=0, likeNumber=0, createdTime=2020-06-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cf719532e2a, moduleTitle=欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cf719532e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594060, encodeId=ee971594060a3, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, objectType=article, longId=194712, objectId=cf45194e12da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf45194e12da, replyNumber=0, likeNumber=70, createdTime=2020-05-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf45194e12da, moduleTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf45194e12da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594059, encodeId=a830159405978, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Brit J Surg：BRCA1和/或BRCA2突变携带者大肠癌风险, objectType=article, longId=192509, objectId=e7681925097d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7681925097d, replyNumber=0, likeNumber=64, createdTime=2020-04-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7681925097d, moduleTitle=Brit J Surg：BRCA1和/或BRCA2突变携带者大肠癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7681925097d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594058, encodeId=5a15159405829, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, objectType=article, longId=190106, objectId=ce37190106a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce37190106a8, replyNumber=0, likeNumber=66, createdTime=2020-03-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce37190106a8, moduleTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce37190106a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594057, encodeId=778a159405e4f, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, objectType=article, longId=186454, objectId=6fbf186454dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf186454dd, replyNumber=0, likeNumber=50, createdTime=2020-01-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf186454dd, moduleTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf186454dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594056, encodeId=5e521594056e5, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet Oncol：80% BRCA突变患者有反应！奥拉帕利治疗前列腺癌患者试验发表, objectType=article, longId=184263, objectId=4011184263e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4011184263e2, replyNumber=0, likeNumber=79, createdTime=2019-12-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4011184263e2, moduleTitle=Lancet Oncol：80% BRCA突变患者有反应！奥拉帕利治疗前列腺癌患者试验发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4011184263e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594055, encodeId=0b81159405512, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%, objectType=article, longId=184163, objectId=972b1841632b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=972b1841632b, replyNumber=0, likeNumber=83, createdTime=2019-12-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=972b1841632b, moduleTitle=PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=972b1841632b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594054, encodeId=21c61594054d5, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=聚焦精准引领未来| BRCA检测推动乳腺癌精准治疗, objectType=article, longId=181403, objectId=5d601814037e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d601814037e, replyNumber=0, likeNumber=82, createdTime=2019-10-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d601814037e, moduleTitle=聚焦精准引领未来| BRCA检测推动乳腺癌精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d601814037e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594053, encodeId=b15215940531a, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=奥拉帕利是gBRCA+、HER2-晚期乳腺癌患者的新选择, objectType=article, longId=181105, objectId=034c181105aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=034c181105aa, replyNumber=0, likeNumber=88, createdTime=2019-10-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=034c181105aa, moduleTitle=奥拉帕利是gBRCA+、HER2-晚期乳腺癌患者的新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=034c181105aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594052, encodeId=f7e51594052c8, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=尼拉帕利再次突破BRCA人群：卵巢癌一线维持整体人群获益, objectType=article, longId=180961, objectId=8ca818096195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca818096195, replyNumber=0, likeNumber=70, createdTime=2019-10-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca818096195, moduleTitle=尼拉帕利再次突破BRCA人群：卵巢癌一线维持整体人群获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ca818096195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594051, encodeId=ccc4159405163, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Eur Urol：男性BRCA1和BRCA2变异位点携带者前列腺癌风险研究, objectType=article, longId=180269, objectId=8b7c18026916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b7c18026916, replyNumber=0, likeNumber=57, createdTime=2019-10-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b7c18026916, moduleTitle=Eur Urol：男性BRCA1和BRCA2变异位点携带者前列腺癌风险研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b7c18026916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594050, encodeId=4b0a159405030, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=2019 USPSTF建议声明：BRCA相关癌症的风险评估、遗传咨询和遗传检测, objectType=article, longId=178272, objectId=d3fd1e827218, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3fd1e827218, replyNumber=0, likeNumber=41, createdTime=2019-08-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3fd1e827218, moduleTitle=2019 USPSTF建议声明：BRCA相关癌症的风险评估、遗传咨询和遗传检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3fd1e827218)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594049, encodeId=57b41594049fc, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JAMA Oncology: BRCA2或为非霍奇金淋巴瘤关键基因, objectType=article, longId=176438, objectId=091c1e6438af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091c1e6438af, replyNumber=0, likeNumber=63, createdTime=2019-07-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091c1e6438af, moduleTitle=JAMA Oncology: BRCA2或为非霍奇金淋巴瘤关键基因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091c1e6438af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594048, encodeId=4ec91594048ee, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet Oncol：宫颈阴道微生物群、BRCA1突变状态和卵巢癌发病风险, objectType=article, longId=175435, objectId=1b8c1e543544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8c1e543544, replyNumber=0, likeNumber=61, createdTime=2019-07-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8c1e543544, moduleTitle=Lancet Oncol：宫颈阴道微生物群、BRCA1突变状态和卵巢癌发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8c1e543544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594047, encodeId=fdac159404ef4, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, objectType=article, longId=175101, objectId=26291e5101bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26291e5101bd, replyNumber=0, likeNumber=82, createdTime=2019-07-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26291e5101bd, moduleTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26291e5101bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594046, encodeId=97261594046a5, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=三阴性乳腺癌：BRCA检测推动三阴性乳腺癌的精准治疗, objectType=article, longId=174828, objectId=f9cd1e48285c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9cd1e48285c, replyNumber=0, likeNumber=128, createdTime=2019-07-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9cd1e48285c, moduleTitle=三阴性乳腺癌：BRCA检测推动三阴性乳腺癌的精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9cd1e48285c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594045, encodeId=581f159404520, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=MOL CELL：什么是BRCA1 / 2缺失的乳腺癌细胞存活必须的?, objectType=article, longId=174769, objectId=f4711e4769b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4711e4769b7, replyNumber=0, likeNumber=76, createdTime=2019-07-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4711e4769b7, moduleTitle=MOL CELL：什么是BRCA1 / 2缺失的乳腺癌细胞存活必须的?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4711e4769b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594044, encodeId=73bc1594044a7, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=欧盟批准辉瑞的PARP抑制剂Talzenna，用于治疗BRCA突变的乳腺癌, objectType=article, longId=172198, objectId=d2b91e21983c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2b91e21983c, replyNumber=0, likeNumber=72, createdTime=2019-06-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2b91e21983c, moduleTitle=欧盟批准辉瑞的PARP抑制剂Talzenna，用于治疗BRCA突变的乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2b91e21983c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Brit J Cancer：高度和体重指数与BRCA1和BRCA2突变携带者卵巢癌风险, objectType=article, longId=169031, objectId=f0df169031d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0df169031d5, replyNumber=0, likeNumber=68, createdTime=2019-06-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0df169031d5, moduleTitle=Brit J Cancer：高度和体重指数与BRCA1和BRCA2突变携带者卵巢癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0df169031d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594042, encodeId=90e3159404266, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, objectType=article, longId=161224, objectId=fd561612244e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd561612244e, replyNumber=0, likeNumber=68, createdTime=2019-02-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd561612244e, moduleTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd561612244e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRCA

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗

2020-06-06

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）

2020-05-27

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Brit J Surg：BRCA1和/或BRCA2突变携带者大肠癌风险

2020-04-20

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后

2020-03-18

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者

2020-01-19

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet Oncol：80% BRCA突变患者有反应！奥拉帕利治疗前列腺癌患者试验发表

2019-12-07

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%

2019-12-06

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

聚焦精准引领未来| BRCA检测推动乳腺癌精准治疗

2019-10-18

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

奥拉帕利是gBRCA+、HER2-晚期乳腺癌患者的新选择

2019-10-15

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

尼拉帕利再次突破BRCA人群：卵巢癌一线维持整体人群获益

2019-10-13

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Eur Urol：男性BRCA1和BRCA2变异位点携带者前列腺癌风险研究

2019-10-01

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

2019 USPSTF建议声明：BRCA相关癌症的风险评估、遗传咨询和遗传检测

2019-08-29

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JAMA Oncology: BRCA2或为非霍奇金淋巴瘤关键基因

2019-07-31

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet Oncol：宫颈阴道微生物群、BRCA1突变状态和卵巢癌发病风险

2019-07-16

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期

2019-07-11

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

三阴性乳腺癌：BRCA检测推动三阴性乳腺癌的精准治疗

2019-07-06

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

MOL CELL：什么是BRCA1 / 2缺失的乳腺癌细胞存活必须的?

2019-07-05

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

欧盟批准辉瑞的PARP抑制剂Talzenna，用于治疗BRCA突变的乳腺癌

2019-06-27

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Brit J Cancer：高度和体重指数与BRCA1和BRCA2突变携带者卵巢癌风险

2019-06-25

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功

2019-02-28

科室
- - 订阅+
  - 更多科室
工具
服务